NZ628395A - Formulations containing trametinib dimethyl sulfoxide - Google Patents
Formulations containing trametinib dimethyl sulfoxideInfo
- Publication number
- NZ628395A NZ628395A NZ628395A NZ62839513A NZ628395A NZ 628395 A NZ628395 A NZ 628395A NZ 628395 A NZ628395 A NZ 628395A NZ 62839513 A NZ62839513 A NZ 62839513A NZ 628395 A NZ628395 A NZ 628395A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cyclodextrin
- dimethyl sulfoxide
- sulfobutylether
- hypromellose
- formulations containing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical compound CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 229960001308 trametinib dimethyl sulfoxide Drugs 0.000 title abstract 2
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 abstract 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 3
- 229960003943 hypromellose Drugs 0.000 abstract 3
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 229960004066 trametinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731597P | 2012-11-30 | 2012-11-30 | |
| PCT/US2013/071816 WO2014085371A1 (en) | 2012-11-30 | 2013-11-26 | Novel pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ628395A true NZ628395A (en) | 2016-10-28 |
Family
ID=50828398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ628395A NZ628395A (en) | 2012-11-30 | 2013-11-26 | Formulations containing trametinib dimethyl sulfoxide |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20150328320A1 (enExample) |
| EP (2) | EP2925299B1 (enExample) |
| JP (1) | JP6232443B2 (enExample) |
| KR (1) | KR102206432B1 (enExample) |
| CN (2) | CN107970214A (enExample) |
| AR (1) | AR093648A1 (enExample) |
| AU (1) | AU2013352369B2 (enExample) |
| BR (1) | BR112015012111A8 (enExample) |
| CA (1) | CA2891346A1 (enExample) |
| CL (1) | CL2015001459A1 (enExample) |
| EA (2) | EA028246B1 (enExample) |
| ES (1) | ES2686730T3 (enExample) |
| IL (3) | IL300664A (enExample) |
| IN (1) | IN2015DN04094A (enExample) |
| MA (1) | MA38121A1 (enExample) |
| MX (1) | MX2015006867A (enExample) |
| MY (1) | MY170427A (enExample) |
| NZ (1) | NZ628395A (enExample) |
| PE (1) | PE20151024A1 (enExample) |
| PH (1) | PH12015501168A1 (enExample) |
| PL (1) | PL2925299T3 (enExample) |
| PT (1) | PT2925299T (enExample) |
| SG (1) | SG11201503688SA (enExample) |
| TN (1) | TN2015000198A1 (enExample) |
| TW (2) | TW201831187A (enExample) |
| UY (1) | UY35157A (enExample) |
| WO (1) | WO2014085371A1 (enExample) |
| ZA (1) | ZA201503346B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102293907B1 (ko) * | 2015-06-30 | 2021-08-26 | 한미약품 주식회사 | 이리노테칸 함유 경구용 고형제제 및 그 제조방법 |
| US20200178569A1 (en) * | 2016-04-29 | 2020-06-11 | Alvin Kershman | Method of Coating an Edible Thermoplastic Pet Chew |
| TW201818936A (zh) | 2016-11-25 | 2018-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種吡啶酮類衍生物醫藥組成物及其製備方法 |
| KR102230721B1 (ko) * | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| JP2022554148A (ja) * | 2019-10-22 | 2022-12-28 | ケミストリーアールエックス | 表皮及び真皮の過形成を治療するための方法 |
| AU2022414970A1 (en) * | 2021-12-15 | 2024-06-27 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
| KR20250008895A (ko) * | 2022-05-12 | 2025-01-16 | 주식회사 지뉴브 | 안정한 액상 제약 제제 |
| WO2025132408A2 (en) | 2023-12-21 | 2025-06-26 | Synthon B.V. | Solvates of trametinib |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6077871A (en) * | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| RU2364596C2 (ru) * | 2004-06-11 | 2009-08-20 | Джапан Тобакко Инк. | ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ |
| ES2408216T3 (es) * | 2004-12-07 | 2013-06-19 | Onyx Therapeutics, Inc. | Composición para la inhibición del proteasoma |
| CN1872055A (zh) * | 2005-06-01 | 2006-12-06 | 李�杰 | 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法 |
| EP2581078B1 (en) * | 2005-10-26 | 2014-12-10 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US20080176946A1 (en) * | 2007-01-16 | 2008-07-24 | Bipar Sciences, Inc. | Formulations for cancer treatment |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| CN101352419B (zh) * | 2007-07-26 | 2010-08-11 | 天津药物研究院 | 一种醋溴茶碱无糖型颗粒剂及其制备方法 |
| KR101478779B1 (ko) * | 2007-11-22 | 2015-01-05 | 에스케이케미칼주식회사 | 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법 |
| RS65800B1 (sr) * | 2009-10-16 | 2024-08-30 | Novartis Ag | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf |
| JP5940078B2 (ja) | 2010-11-11 | 2016-06-29 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | アリールアミノアルコール−置換２，３−ジヒドロイミダゾ［１，２−ｃ］キノリン |
| TWI505828B (zh) * | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| US20130023531A1 (en) | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| ES2590778T3 (es) | 2011-02-28 | 2016-11-23 | Calitor Sciences, Llc | Compuestos de quinolina sustituida |
| AU2012238589B2 (en) * | 2011-04-07 | 2017-02-16 | Bayer Intellectual Property Gmbh | Imidazopyridazines as Akt kinase inhibitors |
| CN102600132B (zh) * | 2012-03-13 | 2014-05-14 | 齐鲁制药有限公司 | 一种含氨磺必利的口服制剂 |
| CN102626394A (zh) * | 2012-03-15 | 2012-08-08 | 合肥科大生物技术有限公司 | 一种精氨酸布洛芬颗粒剂及其制备方法 |
-
2013
- 2013-11-26 AU AU2013352369A patent/AU2013352369B2/en active Active
- 2013-11-26 WO PCT/US2013/071816 patent/WO2014085371A1/en not_active Ceased
- 2013-11-26 KR KR1020157016931A patent/KR102206432B1/ko active Active
- 2013-11-26 MY MYPI2015001232A patent/MY170427A/en unknown
- 2013-11-26 IL IL300664A patent/IL300664A/en unknown
- 2013-11-26 EP EP13857873.7A patent/EP2925299B1/en not_active Revoked
- 2013-11-26 EP EP18173387.4A patent/EP3400933A1/en active Pending
- 2013-11-26 CN CN201711343653.XA patent/CN107970214A/zh active Pending
- 2013-11-26 EA EA201591047A patent/EA028246B1/ru not_active IP Right Cessation
- 2013-11-26 PT PT13857873T patent/PT2925299T/pt unknown
- 2013-11-26 CA CA2891346A patent/CA2891346A1/en not_active Abandoned
- 2013-11-26 MA MA38121A patent/MA38121A1/fr unknown
- 2013-11-26 ES ES13857873.7T patent/ES2686730T3/es active Active
- 2013-11-26 NZ NZ628395A patent/NZ628395A/en not_active IP Right Cessation
- 2013-11-26 US US14/647,606 patent/US20150328320A1/en not_active Abandoned
- 2013-11-26 SG SG11201503688SA patent/SG11201503688SA/en unknown
- 2013-11-26 PE PE2015000701A patent/PE20151024A1/es not_active Application Discontinuation
- 2013-11-26 MX MX2015006867A patent/MX2015006867A/es unknown
- 2013-11-26 JP JP2015545165A patent/JP6232443B2/ja active Active
- 2013-11-26 IN IN4094DEN2015 patent/IN2015DN04094A/en unknown
- 2013-11-26 EA EA201791411A patent/EA201791411A1/ru unknown
- 2013-11-26 IL IL266415A patent/IL266415B2/en unknown
- 2013-11-26 BR BR112015012111A patent/BR112015012111A8/pt not_active IP Right Cessation
- 2013-11-26 PL PL13857873T patent/PL2925299T3/pl unknown
- 2013-11-26 CN CN201380062796.7A patent/CN104902876B/zh active Active
- 2013-11-28 UY UY0001035157A patent/UY35157A/es unknown
- 2013-11-28 TW TW106137040A patent/TW201831187A/zh unknown
- 2013-11-28 AR ARP130104392A patent/AR093648A1/es unknown
- 2013-11-28 TW TW102143365A patent/TW201434468A/zh unknown
-
2015
- 2015-05-13 ZA ZA2015/03346A patent/ZA201503346B/en unknown
- 2015-05-21 IL IL238971A patent/IL238971B/en active IP Right Grant
- 2015-05-22 TN TNP2015000198A patent/TN2015000198A1/fr unknown
- 2015-05-26 PH PH12015501168A patent/PH12015501168A1/en unknown
- 2015-05-29 CL CL2015001459A patent/CL2015001459A1/es unknown
-
2017
- 2017-03-07 US US15/451,888 patent/US20170189408A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ628395A (en) | Formulations containing trametinib dimethyl sulfoxide | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| NZ612157A (en) | Solid oral dosage form for treating cancer | |
| IN2014KN01664A (enExample) | ||
| NZ746271A (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
| PH12016500043A1 (en) | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation | |
| MX2010005346A (es) | Composiciones farmaceuticas. | |
| MX2013007057A (es) | Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos. | |
| PL2254690T3 (pl) | Stabilne w przechowywaniu systemy produktów dla formulacji premiksowych, ich wytwarzanie i zastosowanie | |
| MY177741A (en) | Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate. | |
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| WO2014118808A3 (en) | Ticagrelor solid dispersion | |
| HK1254608A1 (zh) | 改良的地拉罗司制剂及其制备方法 | |
| TN2012000488A1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| MY186229A (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
| MX343234B (es) | Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina. | |
| MX344189B (es) | Formulaciones de mazindol. | |
| WO2014167579A3 (en) | Stable pharmaceutical compositions of tadalafil | |
| WO2012147101A3 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| AU2013338098A8 (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof | |
| TR201007926A1 (tr) | Prasugrel tablet formülasyonları. | |
| TR200907227A2 (tr) | Çözünürlüğü yüksek stabil mikronize granüller. | |
| WO2013171766A3 (en) | Saxagliptin solid dispersion | |
| WO2013124832A3 (en) | Stabilized controlled-release pharmaceutical composition comprising gliclazide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: NOVARTIS AG, CH Effective date: 20160519 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 NOV 2018 BY CPA GLOBAL Effective date: 20171019 |
|
| LAPS | Patent lapsed |